A daily synthesis of the 105 anomaly-flagged stock moves across the ~600 public biotech and life-sciences companies we track. Friday, October 2, 2026 was a split session — the S&P 500 rose 0.74% on a September payrolls print of just 29,000 jobs, while the small-cap biotech proxy finished flat at -0.02% and breadth stayed negative at 318 decliners against 231 advancers on a -0.62% median. Underneath that quiet surface sat six extreme prints: a device name that rallied 25.07% on 11.6x volume after a conference-abstract acceptance, a proteomics story stock that extended a five-day run to +58.5%, a micro-cap that gave back 24% of a one-day 76% spike, and a chromatin company that lost another 31% as its Lilly collaboration collapsed.
A daily synthesis of the 152 anomaly-flagged stock moves across the ~600 public biotech and life-sciences companies we track. Thursday, October 1, 2026 was a broad risk-off session — 110 advancers against 451 decliners on a -2.19% median, with the small-cap biotech proxy down 1.97% while the S&P 500 finished modestly higher. Breadth was the story rather than any single event: one micro-cap device name rose 79.33% on a South American distribution agreement whose binding first order is ten devices, a mid-cap oncology name lost 22.39% on a clinical data disappointment, and the other four names at the top and bottom of the board had no same-day disclosure at all.
A daily synthesis of the 113 anomaly-flagged stock moves across the ~600 public biotech and life-sciences companies we track. Wednesday, September 30, 2026 produced the widest single-name spread in weeks — Liquidia -57.19% and Tenon Medical +49.82% — but the more useful fact is structural: three of the day's six extreme prints (Liquidia, United Therapeutics, MannKind) came from one court ruling on inhaled treprostinil, one came from an equity offering, and two had no same-day catalyst at all. Breadth stayed negative at 305 decliners against 253 advancers on a -0.29% median, even as the small-cap biotech proxy rose 0.59% against a 1.34% decline in broad healthcare.
A daily synthesis of the 95 anomaly-flagged stock moves across the ~600 public biotech and life-sciences companies we track. Tuesday, September 29, 2026 erased Monday's headline distortion: the cross-sectional standard deviation fell from 8.98% to 4.70% while breadth worsened to 319 decliners against 235 advancers on a -0.51% median. The two largest prints were both commercial rather than clinical — Iovance Biotherapeutics at +31.48% on a raised revenue outlook and ClearPoint Neuro at -23.12% on a partner's disappointing 48-month Huntington's dataset — and the remaining four of the top six moved on prior-cycle, dilution, or balance-sheet mechanics rather than on news of their own.
A daily synthesis of the 101 anomaly-flagged stock moves across the ~600 public biotech and life-sciences companies we track. Monday, September 28, 2026 split the tape in two: 273 advancers against 286 decliners on a -0.13% median, with the small-cap biotech proxy at +1.04% against a -0.75% S&P 500 — but one name, Kodiak Sciences at +177.96% on 49.96x volume after a pivotal Phase 3 win, supplied the entire 8.98% cross-sectional standard deviation, and Lifecore Biomedical at +55.24% provided the second-largest print on a $663.7 million take-private.
A daily synthesis of the 75 anomaly-flagged stock moves across the ~600 public biotech and life-sciences companies we track. Friday, September 25, 2026 sold clinical-stage small caps and bought revenue-positive medtech: 360 decliners against 198 advancers on a -0.82% median, with the small-cap biotech index proxy at -0.65% while the broad healthcare proxy gained 0.50% and devices and implant names led every sector bucket — and the six largest movers on the board all closed under $5.
A daily synthesis of the 126 anomaly-flagged stock moves across the ~600 public biotech and life-sciences companies we track. Thursday, September 24, 2026 split the sector in two: 320 decliners against 237 advancers on a -0.54% median, yet the small-cap biotech index proxy still closed +0.55% as the life-science tools complex — Ginkgo Bioworks +18.95%, CareDx +16.70%, Twist Bioscience +15.93%, 10x Genomics +11.35% — printed new 52-week highs, while Wednesday's two biggest gainers, Artelo Biosciences (-30.92%) and Vistagen Therapeutics (-19.95%), surrendered most of their spikes.
A daily synthesis of the 232 anomaly-flagged stock moves across the ~600 public biotech and life-sciences companies we track. Wednesday, September 23, 2026 was the sharpest risk-off session in months: 485 of 573 tracked names closed lower against 73 advancers on a -3.49% median and a -3.35% mean, with XBI -4.12% and IBB -2.00% against a -0.72% S&P 500 as the 10-year Treasury yield touched a 19-year high. Only two of the day's six largest moves carried a fresh company catalyst, both on the winning side, while the biggest loser halved after a strategic-alternatives disclosure bundled with a convertible-note conversion-price reduction.
A daily synthesis of the 138 anomaly-flagged stock moves across the ~600 public biotech and life-sciences companies we track. Tuesday, September 22, 2026 was the broadest advance in weeks: 409 of 573 tracked names finished higher against 153 decliners on a +1.47% median and a +1.83% mean, with XBI +2.30% and IBB +1.76% well ahead of a flat S&P 500. The largest gain and the largest loss were opposite same-day FDA outcomes — a lifted clinical hold that sent FLNA up 39.28% on 26x volume, and an FDA demand for a survival trial that sent CMPX down 31.87% on 7.67x — while a clean maintenance readout repriced VKTX +35.67% and three sub-$3 prints traded on stories that were already a week old.
A daily synthesis of the 75 anomaly-flagged stock moves across the ~600 public biotech and life-sciences companies we track. Monday, September 21, 2026 was a split tape: 279 of 573 tracked names finished higher against 281 decliners on a -0.04% median, while the index proxies gained — XBI +0.96%, IBB +1.27%, SPY +1.55% — on the back of a +12.27% Moderna print and a -7.96% Novo Nordisk. Not one of the six largest movers carried a same-day company disclosure: the extremes were a Nasdaq delisting determination six days old, a sell-the-news reversal on genuinely positive Phase 2 hives data, a post-spike retracement, a low-float grind into a reverse-split vote, a merger-cadence mark in a helium reverse merger, and a pre-readout wedge into an imminent COVID antibody readout.
A daily synthesis of the 260 anomaly-flagged stock moves across the ~600 public biotech and life-sciences companies we track. Friday, September 18, 2026 reversed Thursday's breadth: 322 of 573 tracked names finished lower against 234 advancers on a -0.52% median, with XBI -0.97% and IBB -1.21% as Xenon Pharmaceuticals fell 30.69% on 14x volume after voluntarily pausing new enrolment in its Phase 3 depression studies. Only one of the six largest moves carried a genuine clinical catalyst — the other five were a low-float grind, a post-dilution rebound, an offering priced below the clearing bid and two one-day spikes rounding back.
A daily synthesis of the 153 anomaly-flagged stock moves across the ~600 public biotech and life-sciences companies we track. Thursday, September 17, 2026 delivered the strongest breadth of the recent set: 401 of 573 tracked names finished higher against 161 decliners on a +1.29% median, with XBI +2.64% and IBB +2.31% both well clear of a +1.13% S&P 500. The extremes were structural rather than scientific — Aethlon Medical +374.13% on an all-stock reverse merger with North Immunology backed by a ~$180 million private placement, bioAffinity Technologies +63.55% as a post-split float re-rated, MediciNova +36.90% on a Roth Capital initiation into its COMBAT-ALS window — while Tempest Therapeutics -26.03% gave back a licence-option spike to its placement price, Sunshine Biopharma -18.34% drifted ahead of an authorized reverse split, and Estrella Immunopharma -17.80% kept unwinding a Nasdaq compliance notice.
A daily synthesis of the 129 anomaly-flagged stock moves across the ~600 public biotech and life-sciences companies we track. Wednesday, September 16, 2026 was flat at the index level and slightly negative underneath: 236 of 558 tracked names finished higher against 301 decliners on a -0.42% median, with XBI +0.10%, IBB +0.20% and XLV +0.07% all holding up better than a -0.44% S&P 500. The extremes were structural rather than scientific — PDS Biotechnology +69.25% extending its Nant Capital-led financing re-rating, Tempest Therapeutics +60.18% on 21.1x volume after a CD7 in vivo CAR-T licence option, MediciNova +24.75% on pre-readout accumulation — while Xenetic Biosciences -48.71% repriced an all-stock reverse merger that leaves existing holders about 15% of the combined company, Artelo Biosciences -29.78% sold a mouse-model semaglutide comparison, and Tenon Medical -22.73% unwound a post-reverse-split spike on 0.19x volume.
A daily synthesis of the 143 anomaly-flagged stock moves across the ~600 public biotech and life-sciences companies we track. Tuesday, September 15, 2026 reversed Monday's breadth: only 139 of 573 tracked names finished higher against 423 decliners on a -1.85% median, with XBI -2.27% and IBB -1.27% against a -0.46% S&P 500. The extremes were dominated by give-backs rather than new events — Scinai -36.89% unwinding Monday's 23.85x-volume spike, Profusa -29.34% selling a Nasdaq compliance letter, Radiopharm Theranostics -24.38% giving back positive Phase 2b data — while PDS Biotechnology extended its financing re-rating to +46.65% and Bionano Genomics jumped +17.29% on 25.2x volume after a proposed MolDx coverage determination.
A daily synthesis of the 101 anomaly-flagged stock moves across the ~600 public biotech and life-sciences companies we track. Monday, September 14, 2026 was the rare session in which healthcare advanced while the broad market slipped — XLV +1.45%, XBI +0.90% and IBB +0.82% against SPY -0.45% — and 314 of 573 tracked names finished higher on a +0.49% median. The extremes, though, were set by strategy rather than data: Cellectis -40.97% on 18.67x volume after announcing it would leave allogeneic CAR-T to become an in vivo gene-editing company, and PDS Biotechnology +35.33% on a heavily dilutive $11.3 million private placement first close led by Dr. Patrick Soon-Shiong, who joined the board.
A daily synthesis of the 93 anomaly-flagged stock moves across the ~600 public biotech and life-sciences companies we track. Friday, September 11, 2026 was the first session of the week in which the broad tape was green (SPY +0.85%, IBB +0.14%) while small-cap biotech still slipped (XBI -0.40%, XLV -0.18%), and breadth improved markedly to 242 advancers against 316 decliners on a -0.34% median. Yet the leaderboard was set by calendars rather than catalysts: GT Biopharma +39.32% on 11.49x volume was the only move with a clean same-day disclosure, Processa Pharmaceuticals +12.43% coincided with a conference appearance, and Adial Pharmaceuticals -18.27%, Silexion Therapeutics -15.43% and bioAffinity Technologies -15.34% all fell with no matching news at all.
A daily synthesis of the 111 anomaly-flagged stock moves across the 574 public biotech and life-sciences companies we track on 2026-09-10 (Thursday). A third consecutive risk-off session sent 440 of 574 names lower on a -1.85% median (XBI -1.61%, IBB -1.39%, SPY -0.60%) — yet the leaderboard contained no clinical readout at all. Tenon Medical +117.21% reversed the prior session's -27.38% on the same debt-repayment disclosure as a 667,000-share post-split float turned over hundreds of times; Indaptus Therapeutics +23.08% and Silexion Therapeutics +20.89% rose on a private placement and a conference notice respectively; Lexaria Bioscience -38.64%, NeuroSense Therapeutics -17.21% and HeartSciences -14.81% fell on warrant dilution, a 1-for-20 reverse split and merger-proxy mechanics.
A daily synthesis of the 140 anomaly-flagged stock moves across the 574 public biotech and life-sciences companies we track on 2026-09-09 (Wednesday). Healthcare slipped again — SPY -0.46% but XBI -1.57% and IBB -0.89% — and 439 of 574 tracked names fell on a -1.96% median. Yet the leaderboard was defined by two genuine binary events in opposite directions: Opus Genetics +32.03% on positive OPGx-BEST1 Phase 1/2 Cohort 1 data plus a successful FDA Type C meeting, against Ocugen -19.92% after an interim analysis of OCU410ST in Stargardt disease showed a negative treatment effect in 26 patients. Behind them the tape traded mechanics: Nautilus Biotechnology +20.70% on a same-day Leerink initiation, Skye Bioscience +18.62% on pre-close reverse-merger flow, Lexaria -29.56% on a dilutive warrant exercise, and Tenon Medical -27.38% on a post-reverse-split micro-float unwind with no negative news of its own.
A daily synthesis of the 130 anomaly-flagged stock moves across the 576 public biotech and life-sciences companies we track on 2026-09-08 (Tuesday). Healthcare sold off hard on the first session after Labor Day — SPY -0.55% but XLV -2.52% and IBB -2.17% — with 382 of 576 tracked names down on a -1.33% median. The leaderboard was a financing tape, not a clinical one: PDS Biotechnology +36.36% on a $22.55M Nant Capital PIPE that puts Patrick Soon-Shiong on the board; Indaptus +51.64% and Turn Therapeutics +29.18% on no-news low-float momentum; and on the downside bioAffinity -41.52% as its post-reverse-split float run unwound, Lexaria -33.78% on a dilutive $5.9M warrant-exercise repricing, and Modular Medical -23.37% in a sell-the-news slide. Zero clinical or regulatory data prints among the six top movers for the second consecutive session.
A daily synthesis of the 72 anomaly-flagged stock moves across the ~577 public biotech and life-sciences companies we track on 2026-09-04 (Friday). The broad tape was red — SPY -0.39%, XLV -1.04% — while the tracked small-cap universe closed fractionally green (284 up vs 271 down, median +0.13%), a second consecutive session of inverse coupling between broad-market direction and microcap biotech. Immuron +62.16% on an exclusive U.S. distribution deal for PROIBS with Calmino Group AB; Onconetix +38.02% as its Realbotix robotics-acquisition story extended; NeuroSense +27.19% after its PrimeC strategy reset and an analyst initiation. Losers: BioXcel -37.11% to $0.07 in the last session before its September 8 delisting suspension, Clearmind -31.76% after the tape rejected its robotaxi-charging acquisition, Cyclerion -14.31% on its CVR record date ahead of the Korsana merger close.
A daily synthesis of the 72 anomaly-flagged stock moves across the ~580 public biotech and life-sciences companies we track on 2026-09-03 (Thursday). The broad market rallied (SPY +1.05%) while biotech sold off — 342 names down versus 212 up, median -0.70%, XBI -0.60% — snapping three straight sessions of XBI outperformance. Ultragenyx -44.03% after its Phase 3 Aspire study of apazunersen in Angelman syndrome missed primary and key secondary endpoints; Aptevo -34.23% as a resale registration went effective; BioRestorative -28.76% into its 1-for-20 split. Winners: bioAffinity +31.08% (third straight session), Burning Rock +17.81% on no dated catalyst, Summit +17.33% on fresh ivonescimab survival data.
A daily synthesis of the 99 anomaly-flagged stock moves across the ~580 public biotech and life-sciences companies we track on 2026-09-02 (Wednesday). bioAffinity Technologies +47.95% for a second straight post-reverse-split surge; ENDRA Life Sciences +22.58% on thin-float merger speculation; RenovoRx +19.43% on conference news riding a fully-enrolled Phase 3. TScan Therapeutics -42.80% on a 75% workforce cut and paused Phase 3; BioXcel -21.90% front-running its September 8 Nasdaq delisting; Actuate -15.58% on no news. 391 names up, 176 down, median +1.41%, XBI +1.21% versus SPY +0.44%.
A daily synthesis of the 77 anomaly-flagged stock moves across the ~580 public biotech and life-sciences companies we track on 2026-09-01 (Tuesday). bioAffinity Technologies +44.52% on VA-deal momentum and CyPath Lung positioning amplified by a post-reverse-split thin float; KALA BIO -20.89% on a same-day Virotek distribution LOI the market sold; Enovis -16.51% on its €155M eCential Robotics acquisition offer; Cyclerion +13.32% extends merger-arbitrage positioning into its September 4 CVR record date. 233 names up, 329 down, median -0.49%, XBI +0.55% versus SPY -0.69%.
A daily synthesis of the 83 anomaly-flagged stock moves across the ~580 public biotech and life-sciences companies we track on 2026-08-31 (Monday). RedHill Biopharma +36.16% on 28.8x volume after divesting the Talicia business to Apotex for $18M upfront plus up to $35M in milestones — the only clean same-day catalyst among the six top movers. Cumberland Pharmaceuticals -20.92% as its own $100M Apotex deal-spike unwinds; Celularity +17.09% and RenovoRx +15.57% extend prior-cycle momentum; Aethlon Medical -17.27% and Tectonic Therapeutic -15.95% reverse on light-to-elevated volume. 226 names up, 333 down, median -0.65%, XBI +0.07% versus SPY -0.30%.
A daily synthesis of the 116 anomaly-flagged stock moves across the ~580 public biotech and life-sciences companies we track on 2026-08-28. BioXcel Therapeutics -74.76% on a Chapter 11 filing with Teva as stalking-horse bidder for IGALMI and BXCL501, BioAtla -44.75% after Nasdaq affirmed delisting effective August 31, and Propanc Biopharma -39.46% giving back half of Thursday's +108% mania. On the upside, CollPlant +23.58% on Q2 earnings, Akari Therapeutics +18.76% extending AKTX-101 momentum, and Quoin Pharmaceuticals +18.72% on positive interim QRX003 data plus a ~$30.8M institutional placement. 117 names up, 455 down, median -2.41%, XBI -3.48% versus SPY -0.23%.
A daily synthesis of the 70 anomaly-flagged stock moves across the ~581 public biotech and life-sciences companies we track on 2026-08-27. Celularity +138.53% on a ~$300M MuseCell manufacturing collaboration, Propanc Biopharma +108.41% on new PRP preclinical pancreatic cancer data, and Biomerica +24.27% on a same-day financing and earnings print; on the downside Nexalin -13.63% after approving a 1-for-30 reverse split, while Dogwood Therapeutics and IN8bio faded without fresh news. 239 names up, 329 down, median -0.48%, SPY +0.66% against XBI -0.10%.
A daily synthesis of the 98 anomaly-flagged stock moves across the ~578 public biotech and life-sciences companies we track on 2026-08-26. Generate Biomedicines -20.80% as its lock-up expired, Gossamer Bio -14.96% fading its $250M structured placement, and Profusa -14.90% unwinding after its third reverse split of 2026; on the upside Akari Therapeutics +15.63% extended its ADC-payload run on 5x volume, ENDRA Life Sciences +14.53% printed on a thin-tape continuation, and Capricor +12.91% re-rated after the FDA extended the deramiocel PDUFA to November 22. 207 names up, 355 down, median -0.70%, XBI -0.42% against SPY +0.02%.
A daily synthesis of the 155 anomaly-flagged stock moves across the ~581 public biotech and life-sciences companies we track on 2026-08-25. Autonomix Medical +33.89% on a $4.9M warrant-inducement financing and its FDA-submission path, Actuate Therapeutics +28.46% extending a post-clearance momentum rebound, and Tenax Therapeutics +25.41% positioning into the Phase 3 LEVEL readout expected this month; on the downside Tenon Medical -10.94% and bioAffinity Technologies -10.82% gave back recent pops on thin post-split tapes, and Revelation Biosciences -9.09% faded toward the $1.00 compliance line. 442 names up, 128 down, median +1.78%, XBI +3.00% against SPY +0.32%.
A daily synthesis of the 105 anomaly-flagged stock moves across the ~581 public biotech and life-sciences companies we track on 2026-08-24. Biomea Fusion +16.06% on COVALENT-211 Phase 2 enrollment completion, Aprea Therapeutics +25.75% on sub-$1 momentum ahead of a Q4 2026 ACESOT-1051 data update, and Anbio Biotechnology +16.01% in a technical bounce; on the downside BriaCell -14.99% fading its own Bria-MEL+ milestone announcement, Profusa -16.12% in the fifth leg of its reverse-split unwind, and Adial Pharmaceuticals -13.11% on profit-taking. 222 names up, 339 down, median -0.73%, XBI -0.94%.
A daily synthesis of the 87 anomaly-flagged stock moves across the ~581 public biotech and life-sciences companies we track on 2026-08-21. Werewolf Therapeutics +102.57% on a 23x-volume all-stock merger with Ambros Therapeutics, Lisata Therapeutics +38.39% on a post-termination recovery rally, and Arcturus Therapeutics +22.38% on the continuing mRNA platform bid; on the downside Profusa -27.87% in the fourth leg of its reverse-split unwind, Senti Biosciences -10.87% on post-earnings drift, and Curanex Pharmaceuticals -10.63% in first post-split sessions. 356 names up, 205 down, median +0.91%, with XBI +1.44%.
A daily synthesis of the 163 anomaly-flagged stock moves across the ~581 public biotech and life-sciences companies we track on 2026-08-20. Indaptus +46.81% on a 21x-volume speculative continuation of its strategic-alternatives story, Intensity Therapeutics +16.19% and Actuate +16.04% on low-priced bounces with no fresh catalysts; on the downside Profusa -44.22% in the third leg of its reverse-split unwind, Tenon Medical -38.04% giving back Thursday's patent-driven spike, and Moderna -23.55% in the largest post-rally profit-taking session in over two years. 123 names up, 444 down, median -2.34%, with XBI -3.64% and IBB -2.83%.
A daily synthesis of the 191 anomaly-flagged stock moves across the 581 public biotech and life-sciences companies we track on 2026-08-19. Moderna +176.97% after the Merck-partnered personalized mRNA cancer vaccine met its Phase 3 melanoma goal, Tenon Medical +109.36% on Q2 momentum plus fresh 510(k) and patent news, and Humacyte +26.34% on Phase 3 V007 data published in The Lancet Digital Health led the winners; Profusa -50.62% unwound Wednesday's split-driven squeeze, INVO Fertility -20.98% in a thin-tape reversal with no clean catalyst, and Intelligent Bio Solutions -17.08% sold the news on fiscal-year results. 440 names up, 129 down, median +2.42%, with XBI +5.90% and IBB +6.58%.
A daily synthesis of the 118 anomaly-flagged stock moves across the 581 public biotech and life-sciences companies we track on 2026-08-18. Profusa +506.62% in a post-third-reverse-split low-float squeeze, Amylyx +63.84% on the Phase 3 LUCIDITY avexitide hit with a concurrent $350M offering, and Modular Medical +27.85% on Pivot launch-cycle momentum led the winners; HCW Biologics -15.48% on financing-overhang distribution, Skye Bioscience -13.51% on the Redx Pharma transaction repricing, and Acurx -12.73% in a Tuesday-pop give-back anchored the losers. 305 names up, 260 down, median +0.29%, with XLV +1.60% against SPY -0.68%.
A daily synthesis of the 109 anomaly-flagged stock moves across the 581 public biotech and life-sciences companies we track on 2026-08-17. INVO Fertility +57.47% on a Q2 earnings surprise, Profusa +25.86% in its post-split debut, and Adial Pharmaceuticals +25.38% on a Q2 update and the Azora Therapeutics acquisition led the winners; EyePoint -66.98% on the Phase 3 LUGANO wet-AMD miss, Citius Pharmaceuticals -25.62% on a liquidity-stressed fiscal Q3 report, and BioXcel Therapeutics -25.21% on continued balance-sheet de-risking anchored the losers. 288 names up, 279 down, median +0.05%, with XBI +1.35% and IBB +1.85% against SPY -0.47%.
A daily synthesis of the 109 anomaly-flagged stock moves across the 581 public biotech and life-sciences companies we track on 2026-08-14. Capricor Therapeutics +57.96% after the FDA agreed to review new HOPE-3 follow-up data on deramiocel, Eton Pharmaceuticals +44.26% to a record high on a Q2 revenue beat and guidance raise, and Modular Medical +33.16% on a Pivot launch narrative; Outlook Therapeutics -14.90% on a Q3 miss layered on its $55M offering, HeartBeam -15.34% on a fresh $25M at-the-market agreement, and Quoin Pharmaceuticals -15.87% on a Q2 update the market read as dilutive. 305 names up, 258 down, median +0.30%, with XBI +0.35% against SPY -0.20%.
A daily synthesis of the 114 anomaly-flagged stock moves across the 581 public biotech and life-sciences companies we track on 2026-08-13. Lexaria Bioscience +32.35% on a PegBio GLP-1 drug-delivery partnership, Jupiter Neurosciences +30.15% in a no-clean-catalyst post-split pop, and Omeros +26.55% to a new 52-week high on a swing to Q2 profit and YARTEMLEA momentum; Outlook Therapeutics -19.20% on a $55M deep-discount offering, bioAffinity Technologies -18.98% below its 52-week low with no fresh catalyst, and Insight Molecular Diagnostics -17.56% on continued cash-burn repricing. 227 names up, 337 down, median -0.61%, with XBI -1.59% against SPY +0.70%.
A daily synthesis of the 113 anomaly-flagged stock moves across the 581 public biotech and life-sciences companies we track on 2026-08-12. Palatin Technologies +27.80% into its scheduled fiscal-year results, Dermata Therapeutics +27.78% on the Tome direct-to-consumer launch pivot, and Intelligent Bio Solutions +23.90% on the final FDA 510(k) study for its fingerprint drug-screening system; Silexion Therapeutics -56.13% on a deep-discount offering, Curis -27.71% in a no-clean-catalyst liquidation below its 52-week low, and Bone Biologics -27.60% on sell-the-news into a shelf-life announcement. 303 names up, 259 down, median +0.18%.
A daily synthesis of the 101 anomaly-flagged stock moves across the 581 public biotech and life-sciences companies we track on 2026-08-11. Alamar Biosciences +30.65% on an 82% Q2 revenue beat at a new 52-week high, NeOnc Technologies +24.29% pre-positioning ahead of Tuesday's Phase 2a glioma data, and Alector +23.67% extending its post-earnings re-rating; PDS Biotechnology -64.87% on a strategic refocus that de-prioritized its lead program, Curis -36.89% after filing a 3.73M-share offering, and Silexion -31.00% on a $0.65 deep-discount financing. 320 names up, 240 down, median +0.55%.
A daily synthesis of the 108 anomaly-flagged stock moves across the 581 public biotech and life-sciences companies we track on 2026-08-10. Sionna Therapeutics -91.18% scrapped its cystic fibrosis program after a Phase 2a failure, Tenax Therapeutics -89.77% missed the Phase 3 LEVEL primary endpoint in PH-HFpEF, and Quanterix -39.95% cut its 2026 outlook despite 34% revenue growth; Aligos Therapeutics +36.85% extended a licensing-driven re-rating, Tenon Medical +31.95% bounced on its first post-split session, and Innate Pharma +28.32% on 27x volume marked IPH4502 and lacutamab milestones. 286 names up, 284 down, median +0.04%.
A daily synthesis of the 149 anomaly-flagged stock moves across the 581 public biotech and life-sciences companies we track on 2026-08-07. AVITA Medical +63.58% on a record Q2 with raised 2026 guidance and a Q4 cash-flow breakeven call, OmniAb +37.50% on a milestone-driven Q2 beat with raised guidance, and Arcturus Therapeutics +21.88% on an EPS beat led the winners; CVRx -59.76% on a sharply cut 2026 outlook, QuidelOrtho -24.72% on a lowered outlook with withdrawn free cash flow guidance, and Tenon Medical -22.02% on a 1-for-35 reverse split led the losers. 398 names up, 164 down, median +1.43%.
A daily synthesis of the 133 anomaly-flagged stock moves across the 581 public biotech and life-sciences companies we track on 2026-08-06. Iovance Biotherapeutics +43.09% on a blowout Amtagvi-driven Q2 beat, Ensysce Biosciences +44.83% on closing its Cy Biopharma acquisition with fresh financing, and Sight Sciences +27.75% on raised guidance led the winners; BillionToOne -38.89% sold the news on a beat-without-a-raise, Emergent BioSolutions -29.58% on a NARCAN impairment and guidance cut, and Context Therapeutics -27.27% on a widening loss and Nasdaq bid-price notice. 309 names up, 258 down, median +0.32%.
A daily synthesis of the 90 anomaly-flagged stock moves across the 581 public biotech and life-sciences companies we track on 2026-08-05. Citius Pharmaceuticals +25.45% on subsidiary LYMPHIR commercial momentum, Bluejay Diagnostics +24.00% on SYMON-II enrollment completion, and Geron +21.64% on a Q2 revenue beat led the winners; Autonomix Medical -37.95% reversed its squeeze on dilution mechanics, Vivos -26.31% on financing terms, and Jupiter Neurosciences -25.68% on a 1-for-75 reverse split. 309 names up, 256 down, median +0.24%. The full report is at the bottom.
A daily synthesis of the 170 anomaly-flagged stock moves across the 581 public biotech and life-sciences companies we track on 2026-08-04. Autonomix Medical +434.25% on a patent-catalyst low-float squeeze, Adagio Medical +73.91% on day two of the FDA Expanded Access milestone, and Bruker -21.79% on a Q2 revenue miss with soft FY2026 guidance. 434 names up, 137 down, median +2.41%. The full report is at the bottom.
A daily synthesis of the 113 anomaly-flagged stock moves across the 581 public biotech and life-sciences companies we track on 2026-08-03. Lunai Bioworks rose 23.20% on the naked-short-selling litigation narrative, Adagio Medical jumped 21.60% after the first patient was treated with its vCLAS Ultra ablation system under FDA Expanded Access, and MIRA Pharmaceuticals fell 22.49% as a Nasdaq delisting notice reset the tape.
A daily synthesis of the 108 anomaly-flagged stock moves across the 582 public biotech and life-sciences companies we track on 2026-07-31. Karyopharm collapsed 72.61% on the XPORT-EC-042 Phase 3 failure, BioAge fell 63.62% in sympathy with Novo Nordisk's failed ZEUS NLRP3 readout, and Nuwellis -60.90% gave back Friday's pediatric cardiorenal pop after a $3.4M registered direct offering.
A daily synthesis of the 168 anomaly-flagged stock moves across the 582 public biotech and life-sciences companies we track on 2026-07-30. Nuwellis closed +135.45% on 24.6x volume on a pediatric cardiorenal data print, Bausch Health and Corcept Therapeutics gained ~28% on Q2 beats with raised guidance, while Inovio, Capricor, and Alnylam lost 28-37% on dilution, FDA-adcom overhang, and a Q2 miss.
A daily synthesis of the 102 anomaly-flagged stock moves across the 582 public biotech and life-sciences companies we track on 2026-07-29. Autonomix Medical rose 66.18% on 20.17x volume, while Moleculin, Silexion, and Processa fell 33%–38% on financing and sell-the-news pressure.
A daily synthesis of 91 anomaly-flagged moves across 582 public biotech and life-sciences companies. OPK surged on a Q2 beat, NAUT fell on a broadscale-kit timeline reset, and a defensive healthcare bid outpaced small-cap biotech.
A daily synthesis of the 86 anomaly-flagged stock moves across the 583 public biotech and life-sciences companies we track on 2026-07-27. ENTX +91.22% on 15.66x volume on a $275M BVF-led oversubscribed private placement, FBRX +39.65% on 11.89x volume on argenx's $2.2B acquisition announcement at an 86% premium, GOSS +46.62% on 11.55x volume on reacquisition of worldwide seralutinib rights ahead of a September 2026 NDA submission, MPLT -72.91% on 9.21x volume on a Phase 2 ZEPHYR once-daily dosing-arm failure, CAPR -64.49% on 10.52x volume on an FDA briefing-materials negative read ahead of the July 29 AdCom, and PFSA -28.65% on 12.18x volume on a dilutive acquisition-financing 8-K. The cross-cutting pattern was a 1.64-to-1 advancer ratio at the 583-name aggregate (351 up vs 214 down) with median +0.79% / mean +0.61% / stdev 7.47%, SPY +0.02%, XBI +0.07%, IBB +0.10%, XLV +0.51% with defensive healthcare outperforming broad biotech by 0.44 points, and Devices — Surgical +2.56% as the leading sector bucket above 5 companies.
A daily synthesis of the 93 anomaly-flagged stock moves across the 584 public biotech and life-sciences companies we track on 2026-07-24. ADVB +13.11% extended its post-IPO momentum on confirmation the $25M Helena Global equity line was terminated without any shares being issued, GDTC +12.50% traded on a 24.99x volume ratio on the back of disclosed insider buying, and ZVRA -23.92% was crushed on a negative CHMP opinion from the European Medicines Agency's expert panel on arimoclomol for Niemann-Pick disease type C. LSTA -21.23% collapsed on the formal termination of the Kuva Labs merger after the buyer failed to secure financing. HOWL +18.55% and JUNS -20.92% were the two prior-cycle continuations. The cross-cutting pattern was a 0.41-to-1 advancer ratio at the 584-name aggregate (165 up vs 406 down) with median -1.56% / mean -1.80% / stdev 3.86%, XBI -1.15% underperforming SPY +0.10% by 1.25 points, XLV +0.70% the only positive sector benchmark, and Devices – Surgical +0.25% as the only positive sector bucket above 5 companies.
A daily synthesis of the 74 anomaly-flagged stock moves across 584 public biotech and life-sciences companies. Neuphoria's merger, Advanced Biomed's post-IPO momentum, and a defensive healthcare rotation defined the session.
A daily synthesis of the 86 anomaly-flagged stock moves across the 584 public biotech and life-sciences companies we track on 2026-07-22. ADVB +73.02% on 9.13x volume led the upside as the Advanced Biomed $6.56M IPO closed at $7.08 and the simultaneous termination of the $25M Helena Global equity line removed a 2.1x-equity-base dilution overhang; ARWR +19.03% on 2.41x volume extended on positive Phase 3 top-line results from lead RNA-interference candidate plozasiran in cardiometabolic indications; MSLE +14.72% continued last week's TRAILHEAD momentum on no fresh catalyst. On the downside, TRIB -15.44% sold the news on the announcement of a 1-for-30 reverse ADS split effective 7/24 intended to regain Nasdaq compliance, TRAW -10.60% extended a -17.1% five-day dilution-overhang slide on a July 1 registration statement, ZNTL -10.18% drifted on pre-ESMO 2026 positioning with no same-day catalyst. The cross-cutting pattern was a 0.37-to-1 advancer ratio at the 562-name aggregate (151 up vs 411 down) with median -1.67% / mean -1.37% / stdev 4.67%, XBI -1.55% lagging SPY -0.12% by 1.43 points and IBB -1.22% / XLV -0.51%, and Diagnostics +1.23% average as the only positive sector bucket.
A daily synthesis of the 107 anomaly-flagged stock moves across the 585 public biotech and life-sciences companies we track on 2026-07-21. LSTA -36.45% on 9.24x volume led the downside as the $7.00 Kuva Labs tender offer hit its extended 7/21 outside date with deal-closing risk priced in; ADVB -20.45% sold the news on the effective date of the Helena Global equity-line termination; ERNA -16.39% extended a -25.1% five-day slide on a routine 8-K investor-deck refresh. On the upside, FEMY +19.57% on 4.71x volume, TELO +17.49% on a 2.05x prior-day-bounce off Tuesday's -17% selloff, and PVLA +15.94% on a half-recovery off Tuesday's 21% drop. The cross-cutting pattern was an XBI +2.36% broad-sector rally where the 585-name aggregate printed median +1.63% / mean +1.59% / stdev 4.22%, 412 advancers vs 158 decliners, and 5 of the 6 top movers were Class 1 or Class 5 (mechanical / prior-cycle / no fresh catalyst) — only LSTA carried a real same-week catalyst, going the wrong direction on a buyout-in-jeopardy. Sector leader: Nanotechnology +8.34% across 3 names, with broader leadership from Devices - Imaging +4.20% (8 names) and AI/ML +3.85% (6 names).
A daily synthesis of the 104 anomaly-flagged stock moves across the 585 public biotech and life-sciences companies we track on 2026-07-20. ADVB +76.94% on 25.39x volume led the upside on the close of a $6.56M IPO that retook Nasdaq listing compliance; ONCO +31.54% on the round-$1.00 psychological level after two 2026 reverse splits; PFSA +12.72% on a post-reverse-split drift bounce. KPTI -21.45% on 4.19x volume led the downside on the July 17 retention-PSU program; PVLA -21.04% on sell-the-news continuation off the July 14 corporate presentation; CTOR -17.26% on dilution overhang from the May 15 Q2 results. The cross-cutting pattern was a mechanical-and-prior-cycle tape: 5 of the 6 top movers were Class 1 or Class 5 (no clean fresh catalyst), only ADVB and KPTI carried primary-source catalysts dated within the prior week, and the broad tape underperformed — SPY -0.16%, XBI -2.15%, IBB -1.70%, XLV -1.14%, with 430 decliners vs 142 advancers and 19 of 20 sector categories finishing negative. Sector leader: Devices - Imaging +1.62% across 8 names.
A daily synthesis of the 101 anomaly-flagged stock moves across the 585 public biotech and life-sciences companies we track on 2026-07-17. XNCR +16.86%, JSPR +14.34%, and ETON +13.79% led the upside on a clean ESMO 2026 oral-presentation slot (XmAb819 in ccRCC), the closed Jasper/Kira all-stock merger plus $132M PIPE, and a Canaccord $60 price target on Eton respectively. BRNS -17.09%, GLSI -14.15%, and ISRG -14.15% led the downside — a tape dominated by Intuitive Surgical's Q2 earnings beat-but-no-raise (the day's defining feature), a sell-the-news continuation off GLSI's prior-day FLAMINGO-01 European approval, and a no-clean-catalyst thin-trade sell-off in Barinthus Bio. The cross-cutting pattern was a bellwether-led session: SPY -1.54%, XBI -3.00%, IBB -1.20%, XLV +0.16% — the broad market closed modestly red while biotech ETFs underperformed by 1.46 to 1.80 percentage points, dragged by ISRG's worst day since April 2022 even as 271 of 585 small/mid-cap names finished green (mean +0.11%, median -0.21%, stdev 4.11%). Sector leader: Antibodies +2.09% (n=40).
A daily synthesis of the 137 anomaly-flagged stock moves across the 580 public biotech and life-sciences companies we tracked on 2026-07-16. ATAI +33.40% on Eli Lilly's announced $3.8B acquisition (cash + CVR), CDNA +35.60% on Naveris close + $171.2M Lab Products sale to Eurobio, and JSPR +11.85% on an all-stock Kira merger plus concurrent $132M PIPE led the upside. On the other rail, SNTI -21.19% printed a second-day continuation of yesterday's Celadon-led NewCo spin-off, while MODD -22.67% and KALA -17.76% continued to bleed on prior-month reverse-split + ATM / shelf overhang (the report's prior-cycle catalyst rule applies to all three losers). The cross-cutting pattern was a two-rail day: three discrete M&A prints lifted the advancer side while the loser side was entirely continuation-driven with no fresh primary-source catalysts dated July 16. Sector leader: Psychedelics & Related +6.10% (n=5) on ATAI deal flow.
A daily synthesis of the 87 anomaly-flagged stock moves across the 587 public biotech and life-sciences companies we track on 2026-07-15. IOVA +20.61%, BEAT +17.71%, and RCEL +17.66% led the upside on continuation reads, while SNTI -39.71%, CRDF -32.11%, and QTTB -14.95% led the downside on three clean fresh dilution-print catalysts (Senti spin-off, Cardiff $10M direct, Q32 $200M public). The cross-cutting pattern was a dilution-day where SPY printed +1.26% to a fresh high but biotech ETFs diverged sharply — XBI -4.14%, IBB -3.28%, XLV -2.47% — even as 339 of our 587 small/mid-cap names finished green (mean +0.68%, median +0.58%, stdev 4.62%). Sector leader: Generic Drugs +4.17% (n=5).
A daily synthesis of the 103 anomaly-flagged stock moves across the 587 public biotech and life-sciences companies we track on 2026-07-14. JSPR +18.90%, BTAI +16.75%, and GALT +16.09% led the upside on no fresh news; XAIR -22.96%, SPRO -22.02%, and NTHI -14.81% led the downside on a reverse-split distribution, a $105M royalty-financing sell-the-news reaction, and insider-distribution flow. The cross-cutting pattern was a zero-clean-catalyst day where 6 of 6 top movers were Class 1/4/5 (mechanical, strategic, prior-cycle) and zero were Class 2 (clean clinical / regulatory readout) — a structurally quiet tape where XBI +0.07% essentially matched SPY +0.36%. Sector leader: Psychedelics & Related +3.09% (n=5).
A daily synthesis of the 140 anomaly-flagged stock moves across the 587 public biotech and life-sciences companies we track on 2026-07-13. Q32 Bio (QTTB) ran +90.72% on positive 36-week topline data from Part B of SIGNAL-AA, a bempikibart Phase 2a in alopecia areata. On the downside, Cadrenal (CVKD -16.26%) sold off despite positive late-breaking Phase 2 HIT data after a 2.94M-share secondary offering by selling stockholders hit the tape the same day; Cue Biopharma (CUE -15.93%) closed a previously announced $50M private placement at $33.21; Aardvark (AARD -21.58%) gave back without fresh news as the market lost patience with the delayed Q2 FDA guidance on its ARD-101 clinical hold. The cross-cutting pattern was biotech-specific risk-off on dilution and missing-Q2 guidance, with XBI -2.32% lagging XLV +0.35% by 267bps. Sector leader: Generic Drugs +3.02% (n=5).
A daily synthesis of the 101 anomaly-flagged stock moves across the 587 public biotech and life-sciences companies we track on 2026-07-10. Aardvark rebounded +52.00% on 11.14x volume, Forte added +19.67% as the FB102 vitiligo readout continued to reprice, and Rapid Micro Biosystems gained +17.82% on life-sciences tools follow-through. On the downside, Profusa fell -16.54% in a post-split resale-registration cycle, Anbio Biotechnology lost -15.78% after a mixed shelf filing, and Tvardi gave back -13.68% after its early-week TTI-109 Phase 1 rally. The cross-cutting pattern was a biotech-specific risk-off tape: SPY rose +0.43%, but XBI fell -3.20%, IBB fell -2.68%, and XLV fell -0.82%.
A daily synthesis of the 97 anomaly-flagged stock moves across the 587 public biotech and life-sciences companies we track on 2026-07-09. Forte Biosciences surged +78.33% on 8.38x volume after reporting positive Phase 1b FB102 vitiligo data (29.6% mean FVASI improvement at week 24, p=0.020); TransCode Therapeutics ran +21.84% on a Nasdaq listing-conversion catalyst (Series A/B preferred-to-common); Oncolytics Biotech gained +16.12% on a delayed reaction to the July 8 auditor-change disclosure (E&Y → Baker Tilly, with going-concern explanatory paragraph from prior reports). On the downside, Ionis Pharmaceuticals fell -23.90% on 7.51x volume after the CARDIO-TTRansform Phase 3 trial for eplontersen in ATTR-CM missed its primary efficacy endpoint; Tvardi Therapeutics gave back -24.00% as the post-Phase-1 TTI-109 readout profit-taking continued; TScan Therapeutics fell -15.87% on fading Phase 3 alignment momentum. The session was a clean broad-sector rally: the S&P 500 closed +0.85%, the XBI +0.80%, the IBB +0.69%, the XLV +0.94% — broad healthcare outperformed the S&P 500 and the 5.43% StDev was the signature of marquee single-stock flow (FBRX, IONS) on an otherwise positive tape. Sector leaders: Psychedelics +3.57% (n=5), Diagnostics +2.89% (n=31), Genetics & Genomics +2.87% (n=7). Sector laggards: New England -2.61% (n=7), Stem Cells / Cellular Therapy -0.93% (n=24).
A daily synthesis of the 120 anomaly-flagged stock moves across the 587 public biotech and life-sciences companies we track on 2026-07-08. Tvardi's positive Phase 1 TTI-109 STAT3-inhibitor data extended Wednesday's run (TVRD +61.29% on 8.94x volume, 5d +163.2%); Elicio bounced +24.64% after closing a $15M registered stock sale to fund its KRAS cancer program; TScan Therapeutics ran +17.76% on Phase 3 alignment. On the downside, BioXcel Therapeutics fell -22.87% on 4.99x volume as the market priced in financing risk ahead of IGALMI's at-home sNDA action date (Nov 14, 2026); Context Therapeutics' onapristone extended-release data in ovarian cancer disappointed (CNTX -14.91%); Profusa gave back -14.59% as the post-split squeeze from Wednesday continued to fade. The session was a clean broad-sector fade: the S&P 500 closed -0.31%, the XBI -0.55%, the IBB -0.95%, the XLV -1.30% — broad healthcare underperformed the broad market for the first session in three days. Sector leaders: Psychedelics +3.24% (n=5), Genetics & Genomics +1.63% (n=7). Sector laggards: AI / Machine Learning -3.39% (n=6), Devices — Implants -3.16% (n=10).
A daily synthesis of the 142 anomaly-flagged stock moves across the 587 public biotech and life-sciences companies we track on 2026-07-07. Vertex announced an all-cash $10B acquisition of Crinetics at $85/share, lifting CRNX +98.74% to a 52-week high; Tvardi's positive Phase 1 TTI-109 STAT3-inhibitor data sent TVRD +54.23% on 24x volume; Akari +42.02% on a LoRusso SAB appointment. On the downside, CollPlant called a July 29 EGM to vote on a 16.7x share-capital increase, Elicio was hit with a Pomerantz securities-fraud probe, and CapsoVision extended a multi-week slide with no fresh catalyst. The session was a clean Class-2-and-3 day: a marquee buyout, a clinical readout, a credibility hire, and a financing overhang — not mechanical.
A daily synthesis of the 110 anomaly-flagged stock moves across the 587 public biotech and life-sciences companies we track on 2026-07-06. Celularity ran +29.09% on a sub-$1 short-squeeze; Profusa jumped +21.93% on the eve of a 1-for-25 reverse split; BioXcel cratered -20.29% on the slide toward Nasdaq bid-price compliance; Aktis Oncology fell -16.37% as the radiopharm sector pulled back -5.10%. No clean single-day catalysts in the top six — all six are continuation plays or mechanical events.
A daily synthesis of the 125 anomaly-flagged stock moves across the ~600 public biotech and life-sciences companies we track. Markets were closed Friday, July 3 for the observed Independence Day holiday; all prices reflect Friday, July 2 close. Elicio down 37% on Phase 2 miss plus offering; PPCB up 23% on $5M buyback; reverse splits punished PFSA and CRIS. RNA/Gene Therapy sector led with +3.55% average move.
A daily synthesis of the 125 anomaly-flagged stock moves across the 587 public biotech and life-sciences companies we track on 2026-07-02 (post-market). Elicio cratered -37.35% on a Phase 2 miss in pancreatic cancer; Profusa announced a 1-for-25 reverse split; Propanc surged +22.92% on a $5M buyback. RNA/Gene Therapy and Small-Molecule Pharma led sector averages (+3.55% and +2.23%); Devices — Imaging and Diagnostics lagged (-2.28% and -0.38%). XBI +2.50%, IBB +2.93%, XLV +2.63% — healthcare broadly bid with a sharp divergence underneath.
A daily synthesis of the 143 anomaly-flagged stock moves across the 587 public biotech and life-sciences companies we track on 2026-07-01. Neuphoria cratered -18.76% on 6.84x volume after Merck terminated its partnered Alzheimer's Phase 2. Devices and Diagnostics led sector averages (+2.48% and +2.35%); small-molecule pharma, RNA/gene therapy, and psychedelics lagged. Only one of the top six movers had a clean single-name catalyst on the day — most of the tape was continuation of prior-cycle news.
Deep analysis of the FDA's June 29, 2026 announcement of seven companies selected for the PreCheck Pilot Program — what the selection criteria actually were, who the winners are, what their facility investments look like, and what this means for each company's strategic positioning, the broader CDMO landscape, and the US biopharma supply chain.
Across our internal biotech cohort, 71 publicly-verified upcoming catalyst events sit in the database — 17 with exact PDUFA/readout dates, 51 in sponsor-stated quarters, and 3 still TBD. Today's breakdown covers Q3 2026 (17), Q4 2026 (18), and H1 2027 (12), plus the cross-cutting conference placements, the 41 H1-2026 items we deliberately crossed off the calendar, and one notable caveat (an outlook-therapeutics 4th BLA resubmission) that explains why some 'exact date' PDUFAs are actually long-shot recoveries.
A daily synthesis of the 154 anomaly-flagged stock moves across the 587 public biotech and life-sciences companies we track on 2026-06-26 (post-market, Friday). Curis up 55.98% on 178x volume. Tvardi down 36.44% on 33x volume. Sector rotation into devices, psychedelics, and implants. 154 names moved |%|>= 5%. The full report is at the bottom.
A daily synthesis of the 105 anomaly-flagged stock moves across the ~600 public biotech and life-sciences companies we track. Today's signal: AI-designed and psychedelic-adjacent drug-discovery platforms are being rewarded on clinical validation (ABSI +34.75%, DFTX +18.23%), while orphan-disease single-asset micro-caps are being punished on dilution (CGTX -34.33%, NUWE -33.52%). Includes a 6-class taxonomy of mover signal and the underlying catalysts for the top 6 movers.
No articles in this category match your search or filters.